Neutral endopeptidase inhibition and the natriuretic peptide system

An evolving strategy in cardiovascular therapeutics

Sarah Mangiafico, Lisa C. Costello-Boerrigter, Ingrid A. Andersen, Alessandro Cataliotti, John C Jr. Burnett

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Hypertension and heart failure (HF) are common diseases that, despite advances in medical therapy, continue to be associated with high morbidity and mortality. Therefore, innovative therapeutic strategies are needed. Inhibition of the neutral endopeptidase (NEPinh) had been investigated as a potential novel therapeutic approach because of its ability to increase the plasma concentrations of the natriuretic peptides (NPs). Indeed, the NPs have potent natriuretic and vasodilator properties, inhibit the activity of the renin-angiotensin-aldosterone system, lower sympathetic drive, and have antiproliferative and antihypertrophic effects. Such potentially beneficial effects can be theoretically achieved by the use of NEPinh. However, studies have shown that NEPinh alone does not result in clinically meaningful blood pressure-lowering actions. More recently, NEPinh has been used in combination with other cardiovascular agents, such as angiotensin-converting enzyme inhibitors, and antagonists of the angiotensin receptor. Another future possible combination would be the use of NEPinh with NPs or their newly developed chimeric peptides. This review summarizes the current knowledge of the use and effects of NEPinh alone or in combination with other therapeutic agents for the treatment of human cardiovascular disease such as HF and hypertension. All rights reserved.

Original languageEnglish (US)
Pages (from-to)886-893
Number of pages8
JournalEuropean Heart Journal
Volume34
Issue number12
DOIs
StatePublished - Mar 21 2013

Fingerprint

Neprilysin
Natriuretic Peptides
Angiotensin-Converting Enzyme Inhibitors
Heart Failure
Hypertension
Cardiovascular Agents
Angiotensin Receptors
Therapeutics
Renin-Angiotensin System
Vasodilator Agents
Cardiovascular Diseases
Blood Pressure
Morbidity
Peptides
Mortality

Keywords

  • Evolving strategy in cardiovascular therapeutics
  • Natriuretic peptide system
  • Neutral endopeptidase inhibition

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Neutral endopeptidase inhibition and the natriuretic peptide system : An evolving strategy in cardiovascular therapeutics. / Mangiafico, Sarah; Costello-Boerrigter, Lisa C.; Andersen, Ingrid A.; Cataliotti, Alessandro; Burnett, John C Jr.

In: European Heart Journal, Vol. 34, No. 12, 21.03.2013, p. 886-893.

Research output: Contribution to journalArticle

Mangiafico, Sarah ; Costello-Boerrigter, Lisa C. ; Andersen, Ingrid A. ; Cataliotti, Alessandro ; Burnett, John C Jr. / Neutral endopeptidase inhibition and the natriuretic peptide system : An evolving strategy in cardiovascular therapeutics. In: European Heart Journal. 2013 ; Vol. 34, No. 12. pp. 886-893.
@article{ee2c3cd59cdc4a43b2e569f18895d64d,
title = "Neutral endopeptidase inhibition and the natriuretic peptide system: An evolving strategy in cardiovascular therapeutics",
abstract = "Hypertension and heart failure (HF) are common diseases that, despite advances in medical therapy, continue to be associated with high morbidity and mortality. Therefore, innovative therapeutic strategies are needed. Inhibition of the neutral endopeptidase (NEPinh) had been investigated as a potential novel therapeutic approach because of its ability to increase the plasma concentrations of the natriuretic peptides (NPs). Indeed, the NPs have potent natriuretic and vasodilator properties, inhibit the activity of the renin-angiotensin-aldosterone system, lower sympathetic drive, and have antiproliferative and antihypertrophic effects. Such potentially beneficial effects can be theoretically achieved by the use of NEPinh. However, studies have shown that NEPinh alone does not result in clinically meaningful blood pressure-lowering actions. More recently, NEPinh has been used in combination with other cardiovascular agents, such as angiotensin-converting enzyme inhibitors, and antagonists of the angiotensin receptor. Another future possible combination would be the use of NEPinh with NPs or their newly developed chimeric peptides. This review summarizes the current knowledge of the use and effects of NEPinh alone or in combination with other therapeutic agents for the treatment of human cardiovascular disease such as HF and hypertension. All rights reserved.",
keywords = "Evolving strategy in cardiovascular therapeutics, Natriuretic peptide system, Neutral endopeptidase inhibition",
author = "Sarah Mangiafico and Costello-Boerrigter, {Lisa C.} and Andersen, {Ingrid A.} and Alessandro Cataliotti and Burnett, {John C Jr.}",
year = "2013",
month = "3",
day = "21",
doi = "10.1093/eurheartj/ehs262",
language = "English (US)",
volume = "34",
pages = "886--893",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Neutral endopeptidase inhibition and the natriuretic peptide system

T2 - An evolving strategy in cardiovascular therapeutics

AU - Mangiafico, Sarah

AU - Costello-Boerrigter, Lisa C.

AU - Andersen, Ingrid A.

AU - Cataliotti, Alessandro

AU - Burnett, John C Jr.

PY - 2013/3/21

Y1 - 2013/3/21

N2 - Hypertension and heart failure (HF) are common diseases that, despite advances in medical therapy, continue to be associated with high morbidity and mortality. Therefore, innovative therapeutic strategies are needed. Inhibition of the neutral endopeptidase (NEPinh) had been investigated as a potential novel therapeutic approach because of its ability to increase the plasma concentrations of the natriuretic peptides (NPs). Indeed, the NPs have potent natriuretic and vasodilator properties, inhibit the activity of the renin-angiotensin-aldosterone system, lower sympathetic drive, and have antiproliferative and antihypertrophic effects. Such potentially beneficial effects can be theoretically achieved by the use of NEPinh. However, studies have shown that NEPinh alone does not result in clinically meaningful blood pressure-lowering actions. More recently, NEPinh has been used in combination with other cardiovascular agents, such as angiotensin-converting enzyme inhibitors, and antagonists of the angiotensin receptor. Another future possible combination would be the use of NEPinh with NPs or their newly developed chimeric peptides. This review summarizes the current knowledge of the use and effects of NEPinh alone or in combination with other therapeutic agents for the treatment of human cardiovascular disease such as HF and hypertension. All rights reserved.

AB - Hypertension and heart failure (HF) are common diseases that, despite advances in medical therapy, continue to be associated with high morbidity and mortality. Therefore, innovative therapeutic strategies are needed. Inhibition of the neutral endopeptidase (NEPinh) had been investigated as a potential novel therapeutic approach because of its ability to increase the plasma concentrations of the natriuretic peptides (NPs). Indeed, the NPs have potent natriuretic and vasodilator properties, inhibit the activity of the renin-angiotensin-aldosterone system, lower sympathetic drive, and have antiproliferative and antihypertrophic effects. Such potentially beneficial effects can be theoretically achieved by the use of NEPinh. However, studies have shown that NEPinh alone does not result in clinically meaningful blood pressure-lowering actions. More recently, NEPinh has been used in combination with other cardiovascular agents, such as angiotensin-converting enzyme inhibitors, and antagonists of the angiotensin receptor. Another future possible combination would be the use of NEPinh with NPs or their newly developed chimeric peptides. This review summarizes the current knowledge of the use and effects of NEPinh alone or in combination with other therapeutic agents for the treatment of human cardiovascular disease such as HF and hypertension. All rights reserved.

KW - Evolving strategy in cardiovascular therapeutics

KW - Natriuretic peptide system

KW - Neutral endopeptidase inhibition

UR - http://www.scopus.com/inward/record.url?scp=84875580118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875580118&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehs262

DO - 10.1093/eurheartj/ehs262

M3 - Article

VL - 34

SP - 886

EP - 893

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 12

ER -